Hsin-Pei Shih

Senior Director, Search and Evaluation Business Development
Novo Nordisk A/S

​

Hsin-Pei Shih is currently with Novo Nordisk Rare Disease BD team as a Senior Director of Search & Evaluation.  He has done a variety of deals from acquisition, licensing, to collaboration in different modalities (e.g. small molecule, gene therapy, biologics, and diagnostics) and therapeutic areas over his BD career.  Specifically, in the past 4 years at Novo Nordisk, he played a key role in the acquisition of Forma Therapeutics, collaboration with Life Edit Therapeutics, and licensing programs from Immvention Therapeutics, enriching Novo Nordisk’s Rare Disease pipeline.  Prior to joining Novo Nordisk, he was at Alexion Pharmaceuticals’ Business Development & Corporate Strategy team focussing on external opportunities and executing deals in hematology and metabolic diseases
 
Hsin-Pei also comes with 15 years of drug discovery experience at Forum and Vertex Pharmaceuticals where he supported various programs in rare CNS and pulmonary diseases and made significant contributions to the areas in phenotypic drug screening, chemogenomics, and scientific intelligence.
 
Hsin received his Ph.D. in Biology from the University of North Carolina at Chapel Hill and completed his postdoctoral fellowship at the Howard Hughes Medical Institute. 


 

Speech title & Synopsis

Panel Discussion 1: BD & Licensing

as Panelist